The manufacturers failed to supply the economic analysis required to gain approval. The product was therefore rejected for use in both Type I and Type II diabetes.
The advice document contains a cost comparison table showing the comparative costs of current treatment options and inhaled insulin. The price range for inhaled insulin appears to be at least double that of existing treatments and depending upon dose equivalences this may be up to 8 times the price.
Action: Previous advice has recommended that inhaled insulin should not be initiated in primary care. The SMC advice suggests that this product should not be used at all.
Thanks to PharmaGossip, I had missed the original press release on this item.
|« Opinion Leaders||DREAM or potential nightmare? »|